Cited by 1,310SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approachesCOVID-19 Clinical Research Studies

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Open access
Braun, Julian, Loyal, Lucie, Frentsch, Marco, Wendisch, Daniel, Georg, Philipp, Kurth, Florian, Hippenstiel, Stefan, Dingeldey, Manuela +25 more·2020·Nature

Published version of a preprint

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the rapidly unfolding coronavirus disease 2019 (COVID-19) pandemic 1,2. Clinical manifestations of COVID-19 vary, ranging from asymptomatic infection to respiratory failure. The mechanisms that determine such variable outcomes remain unresolved. Here we investigated CD4+ T cells that are reactive against the spike glycoprotein of SARS-CoV-2 in the peripheral blood of patients with COVID-19 and SARS-CoV-2-unexposed healthy donors. We detected spike-reactive CD4+ T cells not only in 83% of patients with COVID-19 but also in 35% of healthy donors. Spike-reactive CD4+ T cells in healthy donors were primarily active against C-terminal epitopes in the spike protein, which show a higher homology to spike glycoproteins of human endemic coronaviruses, compared with N-terminal epitopes. Spike-protein-reactive T cell lines generated from SARS-CoV-2-naive healthy donors responded similarly to the C-terminal region of the spike proteins of the human endemic coronaviruses 229E and OC43, as well as that of SARS-CoV-2. This results indicate that spike-protein cross-reactive T cells are present, which were probably generated during previous encounters with endemic coronaviruses. The effect of pre-existing SARS-CoV-2 cross-reactive T cells on clinical outcomes remains to be determined in larger cohorts. However, the presence of spike-protein cross-reactive T cells in a considerable fraction of the general population may affect the dynamics of the current pandemic, and has important implications for the design and analysis of upcoming trials investigating COVID-19 vaccines.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-020-2598-9

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • This cross-reactivity largely originates from previous exposure to circulating common cold coronaviruses.

    “This cross-reactivity largely originates from previous exposure to circulating common cold coronaviruses [110-116].”

    From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [114]

    The Discussion says pre-existing spike-reactive CD4+ T cells in SARS-CoV-2-unexposed healthy donors were probably acquired through earlier infections with endemic common-cold coronaviruses. The cross-reactivity section (p. 273) reports responses to endemic coronavirus peptides but describes the proposed origin as a suggestion. It does not establish that this is the origin of cross-reactivity generally, or quantify it as 'largely' responsible. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Lymphocytes from 20% to 50% of unexposed donors display significant reactivity to SARS-CoV-2 Ag peptide pools.

    “lymphocytes from 20% to 50% of unexposed donors display significant reactivity to SARS-CoV-2 Ag peptide pools (Figure 6).”
  • T cell responses against SARS-CoV-2 are highly multi-antigenic and multi-specific, with tens of different epitopes recognized by CD4+ and CD8+ T cells in a given individual.

    “the T cell responses against SARS-CoV-2 are highly multi-antigenic and multi-specific, with tens of different epitopes recognized by CD4+ and CD8+ T cells in a given individual.”
  • The dominant cytokine produced by SARS-CoV-2-specific CD4+ T cells from COVID-19 patients is IFNγ, with a Th1 signature including TNF and IL-2.

    “The dominant cytokine produced by SARS-CoV-2-specific CD4+ T cells from COVID-19 patients is IFNγ (Braun et al., 2020; Grifoni et al., 2020; Rydyznski Moderbacher et al., 2020; Weiskopf et al., 2020), with a clear IFNγ, tumor necrosis factor (TNF), IL-2 protein signature of canonical Th1 cells (Braun et al., 2020; Rydyznski Moderbacher et al., 2020; Peng et al., 2020; Sekine et al., 2020).”

    From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Braun et al., 2020

  • An extended absence of SARS-CoV-2-specific CD4+ T cells is associated with severe or fatal COVID-19.

    “In contrast, the strikingly extended absence of SARS-CoV-2-specific CD4+ T cells was associated with severe or fatal COVID-19 (>day 22 PSO in some cases) (Braun et al., 2020; Rydyznski Moderbacher et al., 2020; Tan et al., 2020a).”

    From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Braun et al., 2020

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Braun, J., Loyal, L., Frentsch, M., Wendisch, D., Georg, P., Kurth, F., Hippenstiel, S., Dingeldey, M., Kruse, B., Fauchere, F., Baysal, E., Mangold, M., Henze, L., Lauster, R., Mall, M. A., Beyer, K., Röhmel, J., Voigt, S., Schmitz, J., Miltenyi, S., Demuth, I., Müller, M. A., Hocke, A., Witzenrath, M., Suttorp, N., Kern, F., Reimer, U., Wenschuh, H., Drosten, C., Corman, V. M., Giesecke-Thiel, C., Sander, L. E., & Thiel, A.
Affiliations
  • Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
  • Charité – Universitätsmedizin Berlin (DE)
  • University Medical Center Hamburg-Eppendorf (DE)
  • Technische Universität Berlin (DE)
  • Robert Koch Institute (DE)
  • Miltenyi Biotec (Germany) (DE)
  • Brighton and Sussex Medical School (GB)
  • JPT Peptide Technologies (Germany) (DE)
Corresponding author
  • Sander, Leif Erik
  • Thiel, Andreas
Venue
Nature
Published
2020-07-29
Volume
587
Issue
7833
Pages
270-274
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W3045971896
Cited by
1,310
References
41
Citations by year
2026: 16 · 2025: 37 · 2024: 91 · 2023: 143 · 2022: 283 · 2021: 480 · 2020: 259 · 2014: 1
FWCI
38.31
Type
journal article
Language
en
Open access
Locations
  • Nature (publishedVersion)
  • medRxiv (acceptedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Figshare (submittedVersion, cc-by)
  • Sussex Research Online (University of Sussex) (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
Funders
  • Deutsche Forschungsgemeinschaft (KFO 339, SFB‐TR84)
  • Bundesministerium für Bildung und Forschung
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords
SARS-CoV-2, COVID-19 pandemic, CD4+ T cells, spike protein, cross-reactive T cells, HCoV-229E, HCoV-OC43, C-terminal epitope, T cell immunity, COVID-19 vaccine design, healthy donors
MeSH terms
Betacoronavirus, COVID-19, SARS-CoV-2, Adult, Aged, Aged, 80 and over, Cell Line, Cross Reactions, Female, Humans, Lymphocyte Activation, Male, Middle Aged, Pneumonia, Viral, CD4-Positive T-Lymphocytes, Coronavirus Infections, Epitopes, T-Lymphocyte, Coronavirus 229E, Human, Coronavirus OC43, Human, Pandemics, Coronavirus NL63, Human, Healthy Volunteers, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review